Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) posted its quarterly earnings data on Monday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06, FiscalAI reports. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter last year, the company posted $0.11 EPS. The company’s quarterly revenue was up 28.4% compared to the same quarter last year.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Management highlighted scale and profitability — over 2.5 million subscribers, full‑year 2025 revenue of $2.35 billion (+59% YoY) and $318 million in Adjusted EBITDA, with $300 million operating cash flow and ~$929 million of cash & investments at year‑end.
• International expansion is a priority: acquisitions of Zava and Livewell and the signed deal for Eucalyptus (up to $1.15 billion, ~$240M upfront) aim to drive >$1 billion of international revenue within three years after a nearly 400% YoY jump to $134M in 2025.
• Executives emphasized diversification beyond GLP‑1s — the company says most revenue is non‑GLP‑1 and has launched labs, low‑testosterone and menopause offerings with early signals (e.g., ~70% of lab customers may be eligible for platform treatments; >95% of testosterone users saw meaningful T increases).
• Near‑term headwinds: guidance embeds an estimated $65 million Q1 revenue timing impact from a shift to 503A shipping cadence and a planned Super Bowl ad that will pressure Q1 EBITDA (Q1 revenue guide $600–625M; Adj. EBITDA $35–55M), though management says underlying demand remains strong.

Hims & Hers Health Trading Down 1.0%

Shares of NYSE HIMS opened at $15.47 on Tuesday. Hims & Hers Health has a twelve month low of $15.15 and a twelve month high of $70.43. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of 28.64, a P/E/G ratio of 2.92 and a beta of 2.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The company’s fifty day moving average is $28.21 and its 200-day moving average is $40.02.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HIMS shares. Citigroup dropped their target price on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday, February 9th. Barclays assumed coverage on Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research cut their target price on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Finally, TD Cowen lowered their target price on shares of Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating for the company in a report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $39.32.

Hims & Hers Health announced that its board has authorized a stock buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q4 beat on EPS and strong revenue growth — HIMS reported $0.08 EPS vs. $0.04 expected and revenue +28% year‑over‑year, showing demand momentum in its subscription and product lines. Hims & Hers Q4 Press Release
• Positive Sentiment: 2026 revenue outlook lifted above consensus — management issued FY2026 revenue guidance of roughly $2.7B–$2.9B, which sits at or above Street estimates and supports longer‑term growth expectations. Hims & Hers forecasts 2026 revenue above estimates
• Neutral Sentiment: Strategic M&A to expand footprint — HIMS closed its acquisition of Eucalyptus for up to $1.15B, accelerating international and product expansion but increasing near‑term cash outlays and integration risk. Hims & Hers Expands Global Footprint With Eucalyptus Acquisition
• Neutral Sentiment: Company highlights longer‑term revenue beat narrative — management reiterated confidence that 2026 revenue will surpass expectations, a supportive signal but one that depends on execution. Hims & Hers forecasts 2026 revenue above estimates
• Negative Sentiment: Q1 guidance came in well below expectations — management set Q1 2026 revenue guidance of $600M–$625M versus Street at ~$650M, signaling near‑term weakness that likely drove the intraday selloff. Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors.
• Negative Sentiment: Profitability edged down — GAAP quarterly profit fell to $20.6M from $26M a year earlier, raising questions about margin pressure as the company scales and spends on marketing/expansion. Hims & Hers Health Fourth-Quarter Profit Falls Despite Higher Revenue
• Negative Sentiment: Heightened regulatory and investor concern — reports note legal/regulatory scrutiny around its compounded weight‑loss drug business and investor unease about costly expansion and high‑profile marketing (e.g., Super Bowl ad) which could pressure margins and sentiment. Hims & Hers’ expansion plans — as well as its Super Bowl ad — have investors worried about profits

Insider Buying and Selling at Hims & Hers Health

In other news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This represents a 9.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 82,963 shares of company stock worth $2,944,621 in the last three months. 17.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. State Street Corp grew its holdings in Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares during the period. Invesco Ltd. boosted its stake in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after acquiring an additional 1,600,004 shares during the period. Marex Group plc increased its holdings in shares of Hims & Hers Health by 162.2% during the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after acquiring an additional 1,496,707 shares during the last quarter. Northern Trust Corp raised its stake in Hims & Hers Health by 1.4% in the 3rd quarter. Northern Trust Corp now owns 2,415,158 shares of the company’s stock valued at $136,988,000 after acquiring an additional 32,236 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Hims & Hers Health by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,398,008 shares of the company’s stock valued at $77,863,000 after acquiring an additional 42,569 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.